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Abstract 
Pre-Exposure Prophylaxis (PrEP) has shown high efficacy in preventing human immunodeficiency virus (HIV) infection 
among men who have sex with men (MSM) in several large clinical trials, and more recently in “real world” reports of 
clinical implementation and a PrEP demonstration project. Those studies also demonstrated high bacterial sexually 
transmitted infection (STI) incidence and raised the discussion of how PrEP may impact STI control efforts, especially 
in the setting of increasing Neisseria gonorrhoeae antimicrobial resistance and the increase in syphilis cases among 
MSM. Here, we discuss STIs as a driver of HIV transmission risk among MSM, and the potential opportunities and chal-
lenges for STI control afforded by expanded PrEP implementation among high-risk MSM.
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Background
There have been exciting recent advances in human 
immunodeficiency virus (HIV) prevention for men 
who have sex with men (MSM) in the last several years, 
especially favorable results of three large clinical trials 
of Pre-Exposure Prophylaxis (PrEP) for HIV prevention 
[1–3]. The implementation of PrEP, and other HIV and 
sexually transmitted infection (STI) prevention strate-
gies, is essential to reduce the estimated 30,000 new HIV 
diagnoses that occur among MSM in the US each year—
with special attention to young MSM and MSM of color, 
groups disproportionally impacted by HIV infection [4, 
5].
New strategies are also needed to address the rise in 
bacterial sexually transmitted infections (Neisseria gon-
orrhea, Chlamydia trachomatis, and syphilis) as well 
among MSM in the US [6, 7]. Syphilis cases are of par-
ticular concern given the 47.9  % increase in diagnoses 
between 2010 and 2014. With that increase in cases, sev-
eral jurisdictions have also noted a rise in more severe 
syphilis complications, including a recent cluster of 18 
ocular syphilis cases in San Francisco, California and 
Seattle, Washington—four of which resulted in at least 
partial visual loss, and two of which are legally blind after 
5 months of follow-up [8].
The convergence of PrEP as a new HIV prevention 
strategy with an ongoing increase in STIs, has sparked 
important discussion about STI control challenges and 
opportunities in the setting of PrEP implementation 
among MSM [9].
STIs as a driver of HIV incidence among MSM
Bacterial STIs have received significant attention as a 
potential driver of HIV infection among MSM since the 
beginning of the HIV epidemic [10, 11]. Several cohort 
studies of MSM initially identified a self-reported history 
of gonorrhea as an independent risk factor for HIV sero-
conversion, and both ulcerative and non-ulcerative STIs 
have been associated both epidemiologically and biologi-
cally with HIV infection [12–20]. Rectal STIs in particu-
lar have been identified as increasing the risk for HIV 
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seroconversion, likely secondary to the higher per-contact 
transmission risk of HIV acquisition in condomless recep-
tive anal intercourse due to the pro-inflammatory micro-
environment, recruitment in HIV target cells, and mucosal 
immune cell activation [21]. A retrospective cohort of 
MSM demonstrated that two or more prior rectal gono-
coccal or chlamydial infections were associated with 8 
times greater risk of HIV seroconversion [14]. Further-
more, a recent modeling analyses estimated the independ-
ent contribution of anorectal gonococcal or chlamydial 
infection on HIV incidence at approximately 15 % [22].
However, the challenge of quantifying the independ-
ent risk of bacterial STIs on HIV seroconversion risk has 
been confounded by sexual risk behavior. In an interest-
ing analysis, Kelley et al., used propensity scores to con-
trol for confounding by behavioral risk and demonstrated 
a nearly threefold increased risk of HIV (Hazard ratio 
2.7; 95 % Confidence interval (CI): 1.2–6.4) among MSM 
diagnosed with rectal gonorrhea or chlamydia in their 
cohort [23]. Syphilis was not associated with HIV acqui-
sition, likely due to the low number of cases. A recent 
report from a cohort of MSM in San Diego diagnosed 
with recent or acute HIV infection between 2004 and 
2014, did however identify syphilis as an independent 
predictor of HIV acquisition [24]. Other studies have also 
demonstrated a strong, independent association between 
recent syphilis infection and HIV acquisition [25].
While the increased risk of HIV acquisition with rec-
tal STIs and syphilis has been demonstrated in controlled 
studies, it has been more difficult to demonstrate in “real 
world” settings. First, HIV and STI testing frequency is 
highly variable for MSM for a variety of patient and pro-
vider factors [26, 27]. Because the majority of STIs are 
asymptomatic in the absence of frequent screening the 
majority will be undiagnosed. In addition, the devel-
opment of community norms regarding non-condom 
sexual risk reduction strategies can potentially decrease 
HIV risk, and concurrently increase STI risk [28]. For 
example, as early as 2006 in San Francisco, there was an 
increase in STI cases without a concurrent increase in 
HIV [29]. Seroadaptive sexual behaviors (e.g., serosort-
ing or strategic positioning) were considered as a pos-
sible non-condom-related HIV risk reduction strategy 
employed by MSM to explain that discrepant observation 
[30, 31]. While seroadaptive behaviors have been associ-
ated with slightly reduced HIV risk (likely secondary to 
the associated difference lower per-contact risk of spe-
cific activities), they may increase risk for other STIs.
PrEP clinical trials among MSM show high HIV risk 
reduction and STI incidence
Several large clinical trials have studied the efficacy of 
PrEP for primary HIV prevention among MSM. The 
Pre-Exposure Prophylaxis initiative (iPrEx) was the first 
large efficacy trial to show the efficacy of co-formulated 
tenofovir disoproxil fumarate/emtricitabine for pri-
mary HIV prevention among MSM [1]. Overall efficacy 
was 44 %, but was significantly higher among those with 
detectable drug levels indicating higher levels of adher-
ence. Sexually transmitted infection incidence was also 
high in iPrEX, and a subsequent analysis showed a trend 
toward decreased reduction in protection among partici-
pants diagnosed with syphilis, although this was not sta-
tistically significant [25].
Results from other recent PrEP clinical trials have 
also demonstrated high STI incidence among study 
participants. The PROUD study demonstrated 86  % 
reduction in HIV risk among high-risk MSM offered 
PrEP as part of routine care at sexual health clinics in 
England [2]. Originally designed as a pilot study the 
HIV incidence among those in the delayed arm was 
8.9/100 person-years. The study was able to target the 
highest risk men, as evidenced by both the high HIV 
incidence in the delayed study arm and that approxi-
mately 50 % of the cohort was diagnosed with at least 
one bacterial STI in follow-up. The Ipergay study also 
showed high PrEP efficacy, 86  % risk reduction when 
used for event-level instead of daily dosing, among 
high-risk MSM in Canada and France [32]. One third of 
study participants in the Ipergay study were diagnosed 
with an STI in follow-up, including six cases of hepa-
titis C (although it’s not clear how many of those were 
sexually transmitted).
STI incidence is also high among PrEP users in “real world” 
settings
Given the high STI incidence observed in PrEP clini-
cal trials, there has been concern about additional risk 
compensation—increased sexual risk behavior—in 
“real world” settings which has the potential to worsen 
the rising bacterial STI incidence. While there were no 
increases in sexual risk behavior overall in a recent PrEP 
demonstration project and report of PrEP implementa-
tion in a large healthcare system, some PrEP users did 
report an increase in risk behaviors, including a decrease 
in consistent condom use [28, 33]. In those recent reports 
approximately 50 % of participants were diagnosed with 
an STI within 12 months of follow-up. The high STI inci-
dence in those studies, suggest that PrEP uptake occurred 
among the men at highest risk for HIV acquisition, but 
without a comparison group it is not possible to identify 
the role that PrEP may have played in modifying sexual 
risk behavior, if any, in the high STI incidence. Those 
studies also highlight the efficacy of PrEP in “real world” 
use as there were no HIV infections among the partici-
pants in the Kaiser San Francisco cohort (n = 657), and 
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only two HIV seroconversions among 557 participants in 
the PrEP Demonstration Project.
Drug resistant gonorrhea is of public health importance
Neisseria gonorrhoeae antimicrobial resistance is of 
urgent public health importance as N. gonorrhoeae have 
developed resistance to all currently available antibiotic 
regimens [34]. The current Centers for Disease Control 
and Prevention (CDC) recommendations for gonorrhea 
treatment include the use of dual therapy with two anti-
microbials [35]. Resistance has developed to all classes of 
antibiotics and there is concern about further spread of 
multi-drug resistant clones among MSM, a core group 
for drug resistant gonorrhea transmission [36]. After a 
brief decline in 2013, the proportion of gonococcal iso-
lates that had an elevated ceftriaxone minimal inhibitory 
concentration (MIC) (>0.125  µg/ml) in the Gonococcal 
Isolate Surveillance Project increased in 2014 [37]. There 
have also been reported cases of isolates with even higher 
ceftriaxone MICs (>0.5 µg/ml) and high-level azithromy-
cin resistance [38, 39].
Increased STI screening and treatment will have 
important implications for STI control strategies to 
reduce the frequency of drug resistant gonococcal 
strains. Oropharyngeal gonococcal infections are an 
important source of ongoing gonorrhea transmission 
and also provide a microbiological environment condu-
cive to the development of extended-spectrum cephalo-
sporin resistance, through gene transfer with commensal 
Neisseria species that normally reside in the throat [40]. 
With improved screening frequency at extragenital 
sites like the oropharynx or rectum using more sensi-
tive nucleic acid amplification tests and routine partner 
treatment, the earlier identification and treatment of 
gonococcal infections could enhance gonorrhea control 
[41, 42].
Increased PrEP uptake is an opportunity to increase STI 
screening
Although current CDC guidelines recommend rou-
tine and repeat screening for syphilis, and behaviorally 
based screening for gonorrhea and chlamydia, the rate 
of screening remains low [43, 44]. The vast majority of 
STIs are asymptomatic at pharyngeal and rectal sites, 
and studies suggest that more than 70 % would be missed 
with urogenital urine-based screening alone [17, 44, 
45]. Many patients are not offered routine extragenital 
screening, even when seen at an STI clinic, and a recent 
study of HIV care providers showed that despite recom-
mendations, routine STI screening was dismal [46]. Cited 
barriers included provider time constraints, difficulty 
obtaining a sexual history, language and cultural barriers, 
and concerns regarding patient confidentiality [46, 47].
PrEP is recommended as part of a comprehensive HIV 
prevention package which includes STI screening, risk 
reduction counseling, and condom promotion. As PrEP 
uptake increase, and is incorporated into various clini-
cal settings, there is a substantial opportunity to improve 
STI screening frequency among high-risk MSM. Quar-
terly STI screening for men taking PrEP has the poten-
tial to increase the detection and treatment of STIs that 
would have otherwise been missed and potentially trans-
mitted to sex partners. In an interesting observational 
cohort study of HIV-positive MSM, a clinic-based inter-
vention of semiannual STI screening and risk reduction 
counseling reduced STI incidence in follow-up by 50  % 
between the 6 and 12 month visits, despite an increase in 
condomless anal sex with seroconcordant partners [48]. 
Increased STI screening coupled with enhanced partner 
services, including routine expedited partner therapy in 
MSM, may also provide an opportunity to engage sex 
partners for testing and treatment for further public 
health impact on both STI and HIV incidence.
While sexual risk compensation among PrEP users has 
been of concern, increased sexual risk behavior has not 
been observed in at least two of the PrEP clinical trials [2, 
33]. PrEP uptake continues to expand among MSM and 
necessitates implementation of currently recommended 
and evaluation of new and innovative STI reduction 
strategies. One such strategy may be chemoprophylaxis 
for bacterial STIs, which could be incorporated into PrEP 
management. A recent pilot study by Bolan et al., demon-
strated a significant reduction (Odds Ratio 0.27; 95 % CI: 
0.09–0.83) in bacterial STIs among MSM randomized to 
receive once daily doxycycline compared to a behavioral 
intervention (contingency management) [49]. That STI 
prevention strategy is also being evaluated as a sub-study 
of Ipergay which has randomized study participants to 
event-driven prophylaxis with doxycycline (two doses of 
doxycycline after each sexual encounter—within at most 
72  h post-event—up to a maximum of six tablets per 
week) vs. no doxycycline [50].
Conclusions
PrEP holds tremendous promise to reduce further HIV 
incidence among MSM, with appropriate targeting and 
implementation, and has along with treatment as preven-
tion become the focus of combination HIV prevention. 
The implementation of PrEP as part of a comprehensive 
HIV prevention program, which includes frequent HIV 
testing, early HIV treatment and viral suppression, STI 
screening and condom promotion, also provides a tre-
mendous opportunity to improve STI screening, treat-
ment, and management with subsequent benefits in 
sexual and reproductive health. There was a steady rise in 
STIs among MSM before the widespread implementation 
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of PrEP, and the impact of the increased adoption of PrEP 
will be telling in the years to come. We have already wit-
nessed a decoupling of STI and HIV incidence in some 
communities—increased STI incidence and lower HIV 
incidence—and it remains to be seen if, and how, PrEP 
will change these epidemiologic curves.
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